Gen Zer Reaches Final Stage of Chemo—Has No Idea Devastating News Is Coming
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
When Alexis Klimpl discovered a grape-sized lump in her breast, her gut immediately told her it was cancer. But due to her young age, she tried to convince herself it couldn't be.
However, a series of tests and scans confirmed the worst: she had stage 2 triple-positive breast cancer at just 24 years old.
Now, one year later, the publicist from San Diego, California, is in remission. But she's also navigating early menopause brought on by her treatment.
"I can't have kids for 10 more years because of the medication I'm on," she told Newsweek.
Klimpl takes Lupron, a drug used to reduce the risk of hormone-receptor-positive breast cancer returning in premenopausal women following surgery and other treatments. She also takes Letrozole, a hormone blocker.
"I never thought I'd be in menopause at 25," she said. "I have 10 to 15 hot flashes a day, night sweats, ongoing hair loss, vaginal dryness and mood swings."
Most women begin the menopausal transition between the ages of 45 and 55, with symptoms often lasting for several years. Breast cancer, too, is typically associated with older women—the American Cancer Society reports that the median age at diagnosis is 62. Although uncommon, a small percentage of cases do occur in women under 45.
L-R: Klimpl with her partner and Klimpl sitting in the hospital during cancer treatment.
L-R: Klimpl with her partner and Klimpl sitting in the hospital during cancer treatment.
Alexis Klimpl
Dr. Mary Jane Minkin, the co-director of the sexuality, intimacy and menopause for cancer survivors program at Smilow Cancer Hospital in New Haven, Connecticut, explained to Newsweek why patients like Klimpl go through a medicated menopause.
"The problem here is that for a woman who has (presumed) estrogen receptor positive breast cancer, all oncologists would want to avoid giving her estrogen, and indeed would probably give her medications to minimize her own body's production of any estrogen from any non-ovarian source," Minkin said.
With no family history of breast cancer, Klimpl and her mother were devastated by the diagnosis.
"I thought I was too young to have cancer," she told Newsweek, explaining that she initially hoped it was just a cyst, but she could feel it growing.
"When I was diagnosed, the doctors didn't know how it happened. They said it's rare at my age. My mom broke down. Seeing her face—I'll never forget that image," Klimpl said.
A friend set up a GoFundMe page for Klimpl that raised $23,000. Half of the funds went toward egg freezing, during which 36 eggs were retrieved. The rest helped cover the costs of six surgeries, each priced at $3,000.
L-R: Klimpl flashing a peace sign and with her mother during a hospitalization.
L-R: Klimpl flashing a peace sign and with her mother during a hospitalization.
Alexis Klimpl/Alexis Klimpl
Klimpl underwent six rounds of chemotherapy over the course of nearly five months and was officially declared cancer-free in January of this year.
Despite genetic tests showing no inherited cancer risk, she chose to have a double mastectomy.
"In my eyes, my breasts betrayed me. They didn't have my back, so I wanted them gone," she said.
Klimpl has since undergone breast reconstruction, which she lightheartedly refers to on Instagram (@lexiklimpl) as "the only positive" of her cancer experience.
Reflecting on the past year, she told Newsweek: "As a young person, you feel invincible—but being diagnosed at such a young age really put my life into perspective."
"It strengthened my relationships with friends and family because they showed up for me in ways I'll never forget. I've realized that we often don't know how to be there for others when we're just trying to keep ourselves together," she said.
"I'm finally at a stage where it feels like everything is behind me. I'm returning to my life—but it's strange. I thought that hearing the words 'cancer-free' would bring instant relief, that it would be the moment the stress disappeared. But it wasn't. Recovery is more complex than I expected."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Trump Administration Says Health Insurance Move Will Save $12 Billion
The Centers for Medicare & Medicaid Services (CMS) has announced it is in the final stages of implementing a new rule that it says will 'lower individual health insurance premiums' by 5 percent on average. CMS said the move is expected to save American taxpayers up to $12 billion in 2026, by 'combating the surge of improper enrollments in the Affordable Care Act (ACA) Exchanges.' Concern has been raised by some that these new measures will push many Americans off their health coverage. 'They will indeed save government money, but only by throwing off the ACA rolls millions of individuals who deserve to be on,' Jonathan Gruber, a professor of economics at Massachusetts Institute of Technology, told Newsweek. Newsweek has contacted CMS via email for comment. According to a CMS release, the new rules are being brought in to tackle 'waste, fraud and abuse' in health insurance markets-an issue that is at the forefront of the Trump administration's policies. A Government Accountability Office (GAO) report from 2024 found that $100 billion was discovered in 'improper payments' in 2023 across the Medicare and Medicaid programs. While wasteful spending in health insurance markets has been targeted by the administration to lower the tax burden for Americans, critics are concerned that sweeping cuts and changes will only push many off health coverage, subsequently driving up costs in the long-term. The new regulation, known as the 2025 Marketplace Integrity and Affordability Final Rule, will target 'improper enrollments' in the Affordable Care Act (ACA) Exchanges via a number of measures. It would repeal the monthly special enrollment period (SEP) for individuals with household incomes at or below 150 percent of the federal poverty level, which CMS called was a kind of loophole for unauthorized enrollments. The policy has been 'used by some agents and brokers to improperly enroll ineligible consumers and perform unauthorized plan switching to gain commissions,' CMS said. Income verification will now be required for most new and auto-renewed enrollments receiving premium subsidies to 'ensure people qualify for the premium subsidies they receive,' CMS added. There will also be additional eligibility requirements for the majority of enrollments through SEPs, in order to close 'loopholes that allowed people to wait to enroll until they needed care,' CMS said. In addition, the rule will reduce advanced payments of the premium tax credit (APTC) by $5 a month for auto-renewed plans without eligibility verification. Most of these policy changes are temporary and will expire after the 2026 plan year-they are simply being used as measures to 'immediately tamp down on improper enrollments and the improper flow of federal funds,' according to CMS. Experts have warned about the impact these measures could have on Americans, with Timothy S. Jost, a professor of law at Washington and Lee University telling Newsweek, 'as many as 1.8 million people could lose ACA coverage.' 'This is an addition to the 4.2 million who will lose coverage because the Congress is not extending the enhanced premium tax credits that were adopted during the Biden administration,' he added. Additional actions being made by CMS in regard to ACA Exchanges include a move to ensure federal ACA subsidies will no longer be available 'to help cover the cost of specified sex-trait modification procedures to align an individual's physical appearance or body with an asserted identity that differs from the individual's sex.' Jonathan Gruber, a professor of economics at Massachusetts Institute of Technology, told Newsweek: 'This is classic doublespeak. These actions will throw millions of people off the ACA rolls by setting up arbitrary administrative barriers that make it hard to enroll.' He added: 'There is undoubtably fraud in ACA exchange enrollment. But this is a blunt solution that will remove many deserving enrollees for every undeserving enrollee and lead to hardship for millions.' Timothy S. Jost, a professor of law at Washington and Lee University, told Newsweek: 'The rules that have just been published will dramatically reduce enrollment in the health insurance exchanges by creating barriers to enrollment leaving many people uninsured. The rules are likely to increase premiums rather than reduce them because the added bureaucratic barriers to enrollment will discourage healthy individuals from enrolling and those covered will be much sicker and more costly. To the extent that rules do reduce premiums for some, it will be primarily because the policies they will be buying will be of lower value, with higher deductibles and co-payments and because the premium tax credits they receive will be reduced.' He added: 'The rule may reduce government expenditures, but simply because it reduces the number of Americans covered and the value of their coverage. There has been some fraud by brokers in the federal marketplace but this was already being addressed by excluding fraudulent brokers.' Robert F. Kennedy Jr., U.S. Health and Human Services Secretary, said: 'We are strengthening health insurance markets for American families and protecting taxpayer dollars from waste, fraud, and abuse. With this rule, we're lowering marketplace premiums, expanding coverage for families, and ensuring that illegal aliens do not receive taxpayer-funded health insurance.' Dr. Mehmet Oz, CMS Administrator, said: 'CMS is restoring integrity to ACA Exchanges by cracking down on fraud, protecting American taxpayer dollars, and ensuring coverage is there for those who truly need it. This is about putting patients first, stopping exploitation of the system, and realigning the program with the values of personal responsibility and fiscal discipline.' The finalized policies will apply to plan years 2025 and 2026, after which they are set to expire. Related Articles Aflac Cyber Breach May Expose Customer Health Data, Social Security NumbersMedicare Update: Lawmakers Introduce Bill to Expand Health Care ProgramNew Yorkers Warned of 38 Percent Spike in Health InsuranceMap Shows States Where People Are Being Removed From Health Care Plan 2025 NEWSWEEK DIGITAL LLC.
Newsweek
2 hours ago
- Newsweek
Ozempic Alternative May Offer Weight Loss Without Injections or Muscle Loss
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new weight loss pill currently undergoing clinical trials could help burn fat and lower blood sugar levels like Ozempic and similar GLP-1 agonists, but without muscles loss as a potential side-effect. This is the conclusion of a new study by an international team of researchers led from the biotech firm Atrogi AB. "This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity," said paper author professor Shane Wright of the Karolinska Institutet in a statement. "Our substance appears to promote health aging weight loss—and, in addition, patients do not have to take injections." Stock image of weight loss pills. Stock image of weight loss pills. celsopupo/iStock / Getty Images Plus GLP-1 agonists like Ozempic work, in part, by altering gut-brain signals to decrease hunger; however, their side effects can include a loss in muscle mass. The new drug, in contrast, is a type of so-called "β2 agonist" which works by activating signaling pathways in the body in such a way that has a positive effect on muscles. Unlike existing β2 agonists, however, it does not have the drawback of overstimulating the heart. In mice models of diabetes and rat models of obesity, the drug has demonstrated benefits for both body composition and blood sugar control. "Our results point to a future where we can improve metabolic health without losing muscle mass," said paper co-author and Stockholm University molecular biologist professor Tore Bengtsson in a statement. "Muscles are important in both type 2 diabetes and obesity—and muscle mass is also directly correlated with life expectancy." While the effectiveness of the new treatment has yet to be evaluated in humans, a phase I clinical trial (which involved 48 healthy subjects and 25 people with type 2 diabetes) has shown that the drug is well-tolerated in humans. A further advantage of the new drug, the team explained, is that because it has a different mechanism of action to Ozempic and other GLP-1 agonists, they could be taken together. "This makes them valuable both as a stand-alone treatment and in combination with GLP-1 drugs," explained Wright. With this initial study complete, researchers are now looking to undertake a larger clinical study to see if the drug offers the same benefits to humans with type 2 diabetes or obesity as it did in the mice models of these conditions. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about weight loss medication? Let us know via health@ Reference Motso, A., Pelcman, B., Kalinovich, A., Kahlous, N. A., Bokhari, M. H., Dehvari, N., Halleskog, C., Waara, E., de Jong, J., Cheesman, E., Kallenberg, C., Yakala, G. K., Murad, P., Wetterdal, E., Andersson, P., van Beek, S., Sandström, A., Alleluia, D. N., Talamonti, E., Youhanna, S., Sabatier, P., Koenig, C., Willems, S., Kemas, A. M., Hutchinson, D. S., Ham, S., Grätz, L., Voss, J., Marchan-Alvarez, J. G., Priede, M., Jaunsleine, K., Spura, J., Kovada, V., Supe, L., Stoddart, L. A., Holliday, N. D., Newton, P. T., Pillon, N. J., Schulte, G., Summers, R. J., Mutule, I., Suna, E., Olsen, J. V., Molenaar, P., Carlsson, J., Lauschke, V. M., Wright, S. C., & Bengtsson, T. (2025). GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell.
Newsweek
2 hours ago
- Newsweek
Cavalier Has Long Day at Vets, What She Demands Once Home Melts Hearts
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A touching TikTok video has captured the hearts of viewers, simultaneously warning them about the health risks accompanying a popular dog breed. The viral clip showed a dog's unexpected request after enduring a grueling three days at the vet for an MRI and numerous tests. All Ginger, a Cavalier King Charles Spaniel, wanted upon returning home was a comforting bath. Since the video was posted, it has received over 997,000 views. "After a long day of having to get an MRI and a lot of tests, Ginger wanted a bath," the owner, @auburnmoak, captioned the video. "Bath time for Ginger after being at the vet for three days." The video shows the pup settling down for a warm bath, finding comfort after what was undoubtedly a stressful experience. Stock photo: A dog is wrapped in a towel after a bath. Stock photo: A dog is wrapped in a towel after a bath. K_Thalhofer/Getty Images The owner shared in the video that the duo had driven four hours to see a vet neurologist that day. Ginger has a progressive condition where her brain is too big for her skull. In the hashtags, she mentioned Chiari malformation and confirmed in the comments that Ginger also suffers from Syringomyelia—the two are related neurological conditions that affect the brain and spinal cord. The footage quickly resonated with pet owners and those familiar with chronic pain conditions. Many commenters expressed profound empathy for Ginger, particularly those who recognized the potential underlying health issues often seen in Cavalier King Charles Spaniels. "I too have Chiari malformation and I don't know what it's like to feel 'good'...ever," one person wrote. "Your poor baby girl." "I have Chiari malformation and I feel her pain," another added. "You're such a great dog momma. I'd never wish this pain on anyone." Another TikToker speculated on the other common, painful condition for the breed. "Syringomyelia, right?" they wrote. "I have two Cavvies and this diagnosis is my fear. Cavvies have so many health they're the sweetest dogs on earth. It's not fair." The video also sparked a discussion about responsible breeding, given the health predispositions of the Cavalier King Charles Spaniel breed. Many commenters urged viewers to avoid supporting breeders focused on the Cavalier—suggesting they adopt Cocker Spaniels instead. Despite Ginger's clear discomfort, viewers were touched by her owner's dedication to her well-being. "I mean, I take baths for pain and it helps ease the anxiety of the day. So, why would a sweet pupper be any different?" one person shared. "I know it was a long day for you, but thank you for putting her needs first. It was so late and you were exhausted and ready for bed but you saw how much she needed that a good doggie mama." The sentiment was summed up by another user who stated the love and heartbreak inherent in the breed. "Cavaliers are such pretty dogs but when I tell you the way her eyes just looked into my soul, I would give her the literal world," they wrote. "My heart absolutely breaks for her seeing her so sad like that." Newsweek reached out to @auburnmoak for comment via TikTok.
